Immutep reports quarterly activities and financials

SYDNEY, Australia - Immutep Limited (NASDAQ:IMMP), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $285 million, has disclosed its quarterly activities and financial results for the second quarter of the fiscal year 2025. The report, filed with the U.S. Securities and Exchange Commission today, provides an overview of the company’s performance up to January 31, 2025. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $7 to $12.

The company, formerly known as Prima BioMed Ltd , operates under the name 03 Life Sciences following a name change on November 19, 2010. It is headquartered in Sydney, with its fiscal year ending on June 30. InvestingPro analysis reveals the company maintains a strong financial position with a current ratio of 18.25, indicating robust liquidity, though it faces challenges with weak gross profit margins.

Immutep’s latest filing, a Form 6-K, is a requirement for foreign private issuers to provide the U.S. Securities and Exchange Commission with an update on significant developments that are not part of the domestic annual and quarterly reporting cycle.

The document filed, Exhibit 99.1, contains the company’s Quarterly Activities Report & Appendix 4C for Q2 FY25. This report details the company’s recent business developments, including progress in its pharmaceutical research and development, partnerships, and financial status.

As a foreign private issuer, Immutep has indicated that it files annual reports under the cover of Form 20-F. The filing does not indicate that Immutep will submit this information in paper as permitted by certain rules, implying the submission is electronic.

Investors and interested parties can access the full report on the SEC’s website to review Immutep’s detailed financial statements and notes on its operational activities. The report is based on a press release statement and aims to provide shareholders with updated and factual information on the company’s status as of the end of January 2025.

The company’s next earnings report is scheduled for February 20, 2025, with trailing twelve-month revenue standing at $2.56 million. For deeper insights into Immutep’s financial health and additional analysis, investors can access more than 10 exclusive ProTips and comprehensive financial metrics through InvestingPro.

In other recent news, biotechnology firm Immutep Ltd has released initial safety data from its phase 1 clinical trial of IMP761, a novel immune control therapy. The company has also reported promising data from its latest study on head and neck cancer treatments, indicating potential advancements in immuno-oncology. Furthermore, Immutep has initiated its TACTI-004 Phase III trial assessing the efficacy of its leading drug candidate in treating patients with first-line non-small cell lung cancer (NSCLC).

Immutep’s price target was raised to $7.00 from $6.00 by Baird following the announcement of new study data for their leading drug candidate, efti, but was later reduced back to $6.00. Analysts from CapitalOne have also initiated coverage of Immutep with an Overweight rating.

The company has received a research and development tax incentive of A$3.6 million from the French government, supporting their ongoing research initiatives. Immutep maintains a strong financial position with more cash than debt and a healthy current ratio of 18.25, providing substantial runway for its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.